IGLV3-6

Across TCGA pan-cancer cohorts, IGLV3-6 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGLV3-6’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where IGLV3-6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGLV3-6 is over-expressed in tumor, although a few such as COAD and STAD show the opposite, repressed pattern.

LUAD, COAD, and STAD are the cancer types where IGLV3-6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV3-6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.661	<.001	7	view →
COAD	Female	III,IV	−1.504	.001	5	view →
STAD	All	IV	−2.570	.013	3	view →
LUSC	Male	All	+0.318	.029	2	view →
KIRC	Male	All	+0.152	.036	2	view →
HNSC	Male	III,IV	+0.302	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGLV3-6–LUAD

Open the LUAD breakdown →